Organization
Bacs Kiskun Megyei Korhaz
3 abstracts
Abstract
Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.Org: University of Texas MD Anderson Cancer Center, Veneto Institute of Oncology IOV - IRCCS, Hospital Universitario 12 de Octubre, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).Org: UT Health San Antonio, MD Anderson Cancer Center, Institut Curie, Saint Cloud, France, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre,